Find Clinical Trial

Home » Find Clinical Trials » Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years

Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years

← Back

Study Phase	Phase 3

Therapeutic Area	Other

Indication	Age related Macular Degeneration

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	TRIMETAZIDINE, S006790

Active Substance Code	S006790

Protocol Code	MC3-06790-001

ISRCTN Code	ISRCTN99532788

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.